# Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

> **NCT00693485** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 70 (actual)

## Conditions studied

- Glaucoma, Open-Angle

## Interventions

- **DRUG:** 400 ug Brimonidine Implant
- **DRUG:** 200 ug Brimonidine Implant
- **DRUG:** Sham (no implant)

## Key facts

- **NCT ID:** NCT00693485
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693485, "Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00693485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*